

BIOCRYST PHARMACEUTICALS INC  
Form 8-K  
August 06, 2015

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **August 5, 2015**

**BioCryst Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**000-23186**  
(Commission File Number)

**62-1413174**  
(IRS Employer Identification No.)

**4505 Emperor Blvd., Suite 200**  
**Durham, North Carolina**  
(Address of principal executive offices)

**27703**  
(Zip Code)

Registrant's telephone number, including area code: **(919) 859-1302**

---

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On August 5, 2015, the Board of Directors of BioCryst Pharmaceuticals, Inc. (the "Company") elected Robert A. Ingram to the Company's Board of Directors. The Company issued a news release reporting this matter on August 6, 2015, and a copy of the news release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

The Company's Board of Directors also appointed Mr. Ingram to serve on each of its Compensation Committee and its Corporate Governance and Nominating Committee effective upon his election to the Board of Directors.

Pursuant to the Company's Stock Incentive Plan, Mr. Ingram will receive an automatic grant of 18,750 stock options upon joining the Board of Directors, and will be entitled to a grant of 15,000 stock options after each annual stockholders' meeting. Mr. Ingram will receive compensation consistent with the Company's director compensation policy as described in the Company's proxy statement for its 2015 annual meeting of stockholders.

**Item 9.01. Financial Statements and Exhibits.**

**Exhibit No.    Description**

99.1	Press Release dated August 6, 2015 entitled "Robert Ingram Appointed to BioCryst's Board Of Directors"
------	--------------------------------------------------------------------------------------------------------

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**BioCryst Pharmaceuticals, Inc.**

---

(Registrant)

/s/ **ALANE BARNES**

---

**August 6, 2015**

---

(Date)

Alane Barnes

*Vice President, General Counsel,  
and Corporate Secretary*

**EXHIBIT INDEX**

**Exhibit No.** **Description**

99.1 Press Release dated August 6, 2015 entitled "Robert Ingram Appointed to BioCryst's Board Of Directors"